Literature DB >> 12390210

The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance.

L Perez Aldana1, M Kato, S Nakagawa, M Kawarasaki, T Nagasako, T Mizushima, H Oda, J Kodaira, Y Shimizu, Y Komatsu, R Zheng, H Takeda, T Sugiyama, M Asaka.   

Abstract

BACKGROUND: Primary and acquired resistance to the antimicrobial agents is a primary reason for the failure of Helicobacter pylori eradication therapies. We assessed the primary antibiotic resistance rates of H. pylori to three different antibiotics and its relationship due to the annual antibiotic consumption in Japan during the period prior to approval of anti-H. pylori therapy in Japan.
MATERIALS AND METHODS: Antibiotic susceptibility was tested using the agar dilution method for clarithromycin, amoxicillin and metronidazole. Isolates were considered resistant when the MIC value was > 8 mg/l for metronidazole, > 1 mg/l for clarithromycin and < 0.5 mg/l for amoxicillin.
RESULTS: Helicobacter pylori isolates were obtained from 593 Japanese patients from 1995 to 2000. Primary resistance of H. pylori to clarithromycin, metronidazole and amoxicillin was found in 11%, 9% and 0.3% strains, respectively. The proportion with clarithromycin resistance significantly increased from 7% in 1997-98 to 15.2% in 1999-2000 (p =.003). During the same period the metronidazole resistance rate also increased from 6.6% in 1997-98 to 12% in 1999-2000 (p =.02). The prevalence of clarithromycin and metronidazole was related to the annual consumption of these antimicrobial agents.
CONCLUSION: Resistance rates for both clarithromycin and metronidazole appear to reflect the annual consumption of these agents. The high rate of clarithromycin resistance in Japan suggests that the effectiveness of clarithromycin-based therapies may be compromised in the near future.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390210     DOI: 10.1046/j.1523-5378.2002.00096.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  31 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Prevalence of Helicobacter pylori in symptomatic patients and detection of clarithromycin resistance using melting curve analysis.

Authors:  Ayse Demet Kaya; C Elif Oztürk; Yusuf Akcan; Mustafa Behçet; A Esra Karakoç; Mihriban Yücel; Müge Mısırlıoglu; Serdar Tuncer
Journal:  Curr Ther Res Clin Exp       Date:  2007-05

3.  Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone.

Authors:  Yi-Chia Lee; Jyh-Ming Liou; Ming-Shiang Wu; Chun-Ying Wu; Jaw-Town Lin
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

4.  New tumor necrosis factor-alpha-inducing protein released from Helicobacter pylori for gastric cancer progression.

Authors:  Masami Suganuma; Miki Kurusu; Kaori Suzuki; Akira Nishizono; Kazunori Murakami; Toshio Fujioka; Hirota Fujiki
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-23       Impact factor: 4.553

5.  Helicobacter pylori and antibiotic resistance.

Authors:  Francis Megraud
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

6.  Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans.

Authors:  Seiji Shiota; Rita Reddy; Abeer Alsarraj; Hashem B El-Serag; David Y Graham
Journal:  Clin Gastroenterol Hepatol       Date:  2015-02-11       Impact factor: 11.382

7.  In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.

Authors:  J-C Yang; P-I Lee; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-25       Impact factor: 3.267

8.  Furazolidone-based triple therapy for H pylori gastritis in children.

Authors:  Elisabete Kawakami; Rodrigo Strehl Machado; Silvio Kazuo Ogata; Marini Langner; Erika Fukushima; Anna Paula Carelli; Vania Cláudia Guimarães Bonucci; Francy Reis Silva Patricio
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

9.  Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.

Authors:  Antonio Francesco Ciccaglione; Luigina Cellini; Laurino Grossi; Leonardo Marzio
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

10.  Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005.

Authors:  Intetsu Kobayashi; Kazunari Murakami; Mototsugu Kato; Seiichi Kato; Takeshi Azuma; Shin'ichi Takahashi; Naomi Uemura; Tsutomu Katsuyama; Yoshihiro Fukuda; Ken Haruma; Masaru Nasu; Toshio Fujioka
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.